Leyden Labs, a Dutch biotechnology company focusing on respiratory viruses, recently received €40 million (about US$47 million) in a Series A round led by GV. Leyden Labs is developing intranasal medicines to prevent infection from a number of respiratory pathogens, including COVID-19.
What did ResoluteAI learn about intranasal medicines and respiratory illnesses?
News on respiratory illnesses and intranasal medicines in 2020 focused on a number of areas, including bat- and bird-borne diseases.
Below are some recent articles on intranasal medicines and respiratory illnesses:
- COVID-19: Nasal vaccine shows promise in mouse study
- Intranasal Vaccines, Vax Data for RWD Exploration, Down Syndrome Impacts: COVID-19 Updates
-
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
News in 2020 on intranasal sprays and respiratory illnesses covered a number of areas.
Clinical trials in progress on intranasal medicines and respiratory illnesses include:
- The Hospital General de México, Instituto Nacional de Cardiologia, and El Instituto Nacional de Neurologia y Neurocirugia are collaborating on a randomized clinical trial of intranasal dexamethasone as an adjuvant in patients with COVID-19.
- The National Institute on Allergy and Infectious Diseases is evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age
- The University of North Carolina is studying anakinra as a rescue treatment for allergic inflammation.
Individuals who have received the most grants on the topic are:
To learn more about how Foundation can help you make connections, schedule a demo or click "Let's talk" below to connect.
